Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 3/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13457577 | 0.84 | LPL (0.43) | EGFRSNCAPDGFRBIDO1TDO2 | |
| SCHEMBL2204914 | 0.82 | DGAT1 (0.49) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL30457508 | 0.82 | EGFR (0.46) | EGFRCSF1RSNCAIDO1TDO2 | |
| SCHEMBL15743609 | 0.82 | EGFR (0.46) | EGFRCSF1RSNCAIDO1TDO2 | |
| SCHEMBL2329181 | 0.82 | SNCA (0.46) | SNCADOT1LPDGFRBPDGFRASRC | |
| SCHEMBL24150785 | 0.81 | NR4A2 (0.47) | EGFRSNCAIDO1TDO2LPL | |
| SCHEMBL29665258 | 0.81 | EGFR (0.52) | EGFRSNCAIDO1TDO2LPL | |
| SCHEMBL1545433 | 0.81 | EGFR (0.46) | EGFRSNCAIDO1TDO2LPL | |
| SCHEMBL1544664 | 0.81 | EGFR (0.52) | EGFRSNCAIDO1TDO2LPL | |
| SCHEMBL23247605 | 0.81 | ALPL (0.48) | EGFRCSF1RSNCAPDGFRBLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884061-B | 1,2, 4-triazine-3-amine derivatives, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20210230138-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-07-29 | — | — | US | disclosed |
| US-11014904-B2 | 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-20190352278-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3569596-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2019-11-20 | — | — | EP | disclosed |
| WO-2018130184-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2018-07-19 | — | — | WO | disclosed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| EP-2321296-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | EGFR 19/4885CSF1R 402/4885SNCA 4609/4885 |
| US-20190352278-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | ADORA2B, ADORA2A, ADORA1 | EGFR 2673/4885CSF1R 1422/4885SNCA 3105/4885 |
| US-20210230138-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | ADORA2B, ADORA2A, ADORA1 | EGFR 2673/4885CSF1R 1422/4885SNCA 3105/4885 |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | EGFR 4809/4885CSF1R 1943/4885SNCA 2885/4885 |
| US-11014904-B2 | 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine | ADORA2B, ADORA2A, ADORA1 | EGFR 2673/4885CSF1R 1422/4885SNCA 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.